Authors’ reply to EisenhutBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5787 (Published 02 November 2016) Cite this as: BMJ 2016;355:i5787
- Saul Faust, professor of paediatric immunology and infectious diseases and director1,
- Norma O’Flynn, clinical director2,
- Caroline Keir, guideline commissioning manager3,
- Martin Allaby, consultant clinical adviser3
- 1NIHR Wellcome Trust Clinical Research Facility, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 2National Guideline Centre, Royal College of Physicians, London NW1 4LE, UK
- 3Centre for Guidelines, National Institute for Health and Care Excellence, London SW1A 2BU, UK
NICE guideline 51 covers the identification, risk assessment, and immediate management of people with suspected sepsis.1 It was not commissioned to replace other NICE guidance of specific conditions or to be a textbook of infectious diseases. In the absence of definitive biomarkers to diagnose sepsis, and in the face of many non-specific symptoms, the NICE guideline provides a pragmatic approach, recognising that at any stage other conditions may be diagnosed and more appropriate management pathways followed.
Eisenhut describes three …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial